Centrexion Therapeutics is transforming the treatment of chronic pain by advancing one of the largest exclusively pain-focused pipelines of novel, non-opioid therapies. We are working to bridge the safety and efficacy gaps in current approaches to chronic pain management.

Our Mission

Chronic pain is a growing problem, not only in terms of the significant number of people that are impacted and the burden this places on our healthcare system, but also because of the abuse and addiction issues, as well as deaths, that have arisen from the high use of opioids to treat chronic pain. Our mission is to relieve the suffering associated with chronic pain by developing treatments that address the safety and efficacy gaps in the current treatment paradigm.
Our broad pipeline represents our mission to attack the problem of chronic pain in many different ways, including a topical gel, a deeper tissue injection, a spinal delivery, and three separate oral treatments. We believe that our non-opioid approach to chronic pain treatment has the potential to provide effective therapeutic options while avoiding the abuse and addiction epidemic that has resulted from high use of opioid drugs.

Centrexion / Management

Jeff-Kindler

Jeffrey B. Kindler

Chief Executive Officer

Jim-Campbell

James N. Campbell, M.D.

President, Chief Scientific Officer

Randall-Stevens

Randall Stevens, M.D.

Chief Medical Officer

Peter-Hanson

Peter Hanson, DVM, Ph.D.

Chief Veterinary Officer

Kerrie-Brady

Kerrie Brady, BPharm, MS, MBA

Chief Business Officer

Gregg-Beloff

Gregg Beloff, J.D., MBA

Chief Financial Officer

"We are committed to bettering the lives of patients in pain and their caregivers"

Centrexion / Board

Jeff-Kindler

Jeffrey B. Kindler

Chief Executive Officer

Jim-Campbell

James N. Campbell, M.D.

President, Chief Scientific Officer

sol-barer

Sol Barer, Ph.D.

Chairman

isaac-blech

Isaac Blech

Vice Chairman

arnie-oronsky

Arnie Oronsky, Ph.D.

Director

Shawn-Tomasello

Shawn Tomasello

Director

Clinical Advisory Board

Duncan Lascelles, BVSc, Ph.D.

Steve Cohen, M.D.

Nathaniel Katz, M.D., M.S.

Tony Yaksh, M.D. Ph.D.

Robert Dworkin, Ph.D.

Duncan Lascelles, BVSc, Ph.D.

Duncan Lascelles, BVCs, Ph.D., is a professor of small animal surgery, director of integrated pain management service, director of the Comparative Pain Research Laboratory and the associate director of the Center for Comparative Medicine and Translational Research at North Carolina State University. His research is focused on developing algometry methods in spontaneous disease animal models and probing tissues from well-phenotyped animals with to understand the neurobiology. The aim of such research is to improve pain control in companion animals and facilitate analgesic development in human medicine. Dr. Lascelles is board-certified in small animal surgery by the Royal College of Veterinary Surgeons, the European College of Veterinary Surgeons and the American College of Veterinary Surgeons. Dr. Lascelles completed a Ph.D. in aspects of pre-emptive/perioperative analgesic at the University of Bristol, U.K., after graduating from their veterinary program. He went on to complete his surgical residency at the University of Cambridge, U.K., followed by a fellowship in oncological surgery at Colorado State University.

Steve Cohen, M.D.

Steven Cohen, M.D., is a professor of anesthesiology and critical care medicine and the director of the Blaustein Pain Treatment Center, Medical Education and Quality Improvement Pain Management Division at Johns Hopkins. He also acts as director of pain research at Walter Reed National Military Medical Center. Steven’s major contributions to pain research include the development of an FDA approved technique for treating sacroiliac joint pain (lateral branch radiofrequency denervation), inventing the intravenous ketamine test to help guide treatment in patients with chronic pain and performing the first studies evaluating the epidural administration of biological agents for pain. In 2014, Steven was listed as one of the top 10 experts in the world for back pain based on quantitative analysis of publications. In addition to his academic work, Steven is a retired Colonel in the U.S. Army. He serves as the Reserve Liaison to the Pain Management Consultants to the U.S. Army and Navy Surgeons General, and previously served as an inaugural member of the U.S. Army Medical Advisory Board. His research was instrumental in the passing of the Military Pain Care Act of 2008. Steven received his medical degree at the Mount Sinai School of Medicine, completed an anesthesiology residency at Columbia University and a pain management fellowship at Massachusetts General Hospital.

Nathaniel Katz, M.D., M.S.

Nathaniel Katz, M.D., M.S., is internationally recognized for his expertise in pain management, analgesic clinical trials and investigations focusing on opioids and risk management. As president and founder of Analgesic Solutions, Nathaniel established the company with the mission of modernizing the design and conduct of pain clinical trials to advance the scientific quality of pain clinical research and to empower effective treatments for patients. Prior to founding Analgesic Solutions, Nathaniel was a staff neurologist in the Pain Management Center of Brigham & Women’s hospital where he also founded the Pain Trials Center, a clinical analgesic research unit. He also founded the Pain & Symptom Management Program at Dana-Farber Cancer Institute. In addition to having served on numerous scientific advisory boards, Nathaniel has served as chairman to the Advisory Committee of Anesthesia, Critical Care and Addition Products Division of the FDA, as well as to the National Initiative on Pain Control. He is currently an adjunct assistant professor of Anesthesia at Tufts University School of Medicine and an active member of IMMPACT (Initiative on Methods, Measurements, and Pain Assessment in Clinical Trials). Nathaniel completed his neurology residency at Tufts New England Medical Center and later entered a pain management fellowship in the Department of Anesthesia at Brigham & Women’s Hospital. He received his medical degree from the Medical College of Pennsylvania and his M.S. in biostatistics from Columbia University.

Tony Yaksh, M.D. Ph.D.

Tony Yaksh, M.D., Ph.D. is a professor in anesthesiology and pharmacology at the University of California, San Diego, where he is also vice chairman for research in anesthesiology and co-director of the Pain and Symptom Management Core at the UCSD Regional Cancer Center. His lab has been noted for its achievements in being the first to publish data on the effects of spinal baclofen; conducting the preclinical evaluations of analgesic actions of conopeptides in support of the clinical development of Prialt®; and for providing the pivotal data lead-in to the IND for Depofoam morphine for epidural use. Tony is the recipient of numerous awards, including the American Society of Anesthesiologists Award for Excellence in Research, the Bonica Award from the International Association for the Study of Pain, and most recently, the Lifetime Achievement Award from the North American Neuromodulation Society. Tony obtained his Ph.D. degree from Purdue University before serving in the United States Army, working in the biomedical laboratory at Edgewood Arsenal.

Robert Dworkin, Ph.D.

Robert Dworkin, Ph.D., is a professor of anesthesiology, neurology, oncology and psychiatry, and director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry. Robert’s research has been funded by the National Institute of Health, the Department of Defense and various pharmaceutical companies. In particular, with funding from the FDA, Robert is examining studies and other efforts to improve the efficacy of analgesic clinical trials with the support of ACTTION public-private partnership, in which he also serves as director. Additionally, Robert is the associate editor of Pain, on the editorial board for both the Journal of Pain and the Current Pain and Headache Reports, and is a professional advisory board member for the American Chronic Pain Association. He is also the recipient of numerous awards such as the Mitchell B. Max Award for Neuropathic Pain by the American Academy of Neurology, the John and Emma Bonica Public Service Award by the American Pain Society and the John J. Bonica Award of the Eastern Pain Association. Robert received his B.A. from the University of Pennsylvania and his Ph.D. from Harvard University.

Jeffrey B. Kindler

Chief Executive Officer

Jeff Kindler joined Centrexion Therapeutics as the chief executive officer in 2013. He brings more than three decades of business experience and has held leadership positions at some of the world’s most recognized companies. Jeff is also executive chair of vTv Therapeutics; venture partner at Lux Capital; managing director at Starboard Capital and the global chair for the GLG Institute. Prior to joining Centrexion, Jeff was the chairman and CEO of Pfizer, the world’s largest research-based biopharmaceutical company. As CEO, he led Pfizer’s $68 billion merger and acquisition of Wyeth, diversified its product portfolio, improved its research and development pipeline and reshaped the company’s commercial, innovation and leadership models to drive growth and cultural change. Earlier in his career, Jeff served as the executive vice president and general counsel for McDonald’s Corporation and was the vice president of litigation and legal policy for the General Electric Company. Prior to GE, Jeff practiced civil and criminal litigation as a Partner of William & Connolly. Jeff holds a B.A. from Tufts University and a J.D. from Harvard University.

Jeff-Kindler

James N. Campbell, M.D.

President, Chief Scientific Officer

James Campbell, M.D. is a founder, president and chief scientific officer of Centrexion. Jim is Professor Emeritus of neurosurgery at Johns Hopkins University School of Medicine. He has published over 100 peer-reviewed scientific studies in the field of pain research, which have been recognized through many national honors. In 1996, Jim was president of the American Pain Society. Prior to joining Centrexion, he served as the CEO of Arcion Therapeutics, a biotech company developing topical products for the treatment of neuropathic pain. Earlier in his career, he served as the CEO for Vallinex, Inc. He served as the founder of the American Pain Foundation and for 10 years was chairman of the board. He also served as board observer and co-founder of CNS Therapeutics, and was co-founder and on the board of directors of Amplimmune. Jim holds a B.A. in psychology with high honors and high distinction from the University of Michigan and received his M.D. from Yale University. He received his training in Neurosurgery at the Johns Hopkins Hospital, and is a Diplomate of the American Board of Neurological Surgery.

Jim-Campbell

Randall Stevens, M.D.

Chief Medical Officer

Randall Stevens, M.D. joined Centrexion Therapeutics as the chief medical officer in April 2015. Randall is a board certified internist and rheumatologist with more than 25 years in pharmaceutical medicine. Prior to joining Centrexion, he served as the corporate vice president, head of inflammation and immunology clinical development of Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he has been a clinical professor of medicine at Robert Wood Johnson School of Medicine since 1990 and a board member for Outcome Measures Rheumatic Clinical Trails (OMERACT) since 2007. Randall has authored or co-authored more than 40 peer-reviewed publications. He holds a B.A. in chemistry and Spanish and a M.D. from Case Western Reserve University School of Medicine.

Randall-Stevens

Peter Hanson, DVM, Ph.D.

Chief Veterinary Officer

Peter Hanson joined Centrexion Therapeutics as the chief veterinary officer in June 2014. Peter also has responsibility for chemistry, manufacturing and controls (CMC) and clinical operations. He is a Diplomate of the American College of Veterinary Surgeons with nearly 20 years in pharmaceutical medicine. Prior to Centrexion, Peter was the head of research and development and medical affairs for Abbott Animal Health. From 1996 to 2012 he worked at Merial, most notably serving as the global head, project and portfolio management, the head of pharmaceutical R&D and the executive director, pharmaceutical R&D projects. Peter holds a B.A. in biology and a DVM from the University of Minnesota. He holds a residency certificate, an M.S. and Ph.D. in veterinary science from the University of Wisconsin-Madison.

Peter-Hanson

Kerrie Brady, BPharm, MS, MBA

Chief Business Officer

Kerrie Brady is a founder and chief business officer of Centrexion Therapeutics. Kerrie’s career includes 30 years of experience as an international pharmaceutical executive. Prior to joining Centrexion, Kerrie was the chief operations officer for Vallinex Inc., a company she founded as a spin out from Arcion Therapeutics, Inc., a biotech company developing topical products for the treatment of neuropathic pain. Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. Kerrie holds a BPharm from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in biopharmaceuticals from the University of New South Wales. In 2016, Kerrie was named to the PharmaVOICE100 for her contributions to the life-sciences industry.

Kerrie-Brady

Gregg Beloff, J.D., MBA

Chief Financial Officer

Gregg Beloff joined Centrexion Therapeutics as chief financial officer in 2015. Additionally, Gregg is a founder and managing director with Danforth Advisors. He brings more than 20 years of experience in the life sciences and technology industries ranging from venture-backed start-ups to publicly traded companies to his work with Danforth Advisors’ clients. Previously, he served as the CFO of two public and three privately-held companies. In these roles, he managed finance, accounting, corporate communications, human resources, information technology, facilities, legal, intellectual property, business development and manufacturing functions. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill, where he underwrote financings for and provided buy- and sell-side M&A counsel to biotechnology, medical device and healthcare information technology companies. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg holds a B.A. from Middlebury College, an MBA from Carnegie Mellon University and completed his J.D. at the University of Pittsburgh School of Law.

Gregg-Beloff

Sol Barer, Ph.D.

Chairman

Sol Barer, Ph.D. is a founder and chairman of the board of directors of Centrexion Therapeutics. Sol brings more than 30 years of experience in the biotechnology industry. He is the managing partner of SJBarer Consulting and was a founder of Celgene, a global biopharmaceutical company. From 1987 to 2011, Sol led Celgene in various executive roles including president, COO and CEO. He also served as the executive chairman and chairman of the company’s board of directors. Sol currently serves as chairman of the board of Edge Therapeutics, Inc., Cerecor, Inc., ContraFect Corp., InspireMD, Inc., Medgenics, Inc. and RestorGenex. He is also on the boards of a number of other biotechnology and pharmaceutical companies including Amicus Therapeutics, Inc., Aegerion Pharmaceuticals, Inc. and Teva Pharmaceuticals. Sol holds a B.S. from Brooklyn College and a Ph.D. in organic chemistry from Rutgers University.

sol-barer

Isaac Blech

Vice Chairman

Isaac Blech is a founder and vice chairman of Centrexion Therapeutics. Isaac, one of the most successful founders in the biotechnology industry, brings with him more than 35 years of experience. As a pioneer in the field, he has established 10 biotechnology companies. His current roles include founder and vice chairman of Cerecor, Inc., a company developing new treatments for central nervous system disorders, and director of ContraFect Corporation, a company developing therapies for infectious diseases. He is also vice chairman of Edge Therapeutics, WaveGuide Corporation, X-4 Pharmaceuticals, Aridis, Sapience Therapeutics and Regenovation, Inc., and director of Medgenics. Throughout his career, Isaac has established multiple companies responsible for major advances in oncology, infectious disease and cystic fibrosis, including Celgene Corporation, ICOS Corporation, Pathogenesis Corporation, Nova Pharmaceutical Corporation and Genetic Systems Corporation. Isaac holds a B.A. from Baruch College.

isaac-blech

Arnie Oronsky, Ph.D.

Director

Arnie Oronsky, Ph.D. is a founder and board member of Centrexion Therapeutics. Arnie currently serves as a general partner and managing director at InterWest Partners LLC, a venture capital firm. Earlier in his career, Arnie led pharmaceutical research as vice president for discovery research for the Lederle Laboratories division of American Cyanamid Company. He is a board member of Applied Genetic Technologies Corporation, Drais Pharmaceuticals, Dynavax Technologies, EpicentRx, Integrated Diagnostics, PMV Pharma, Potenza Therapeutics, Sera Prognostics, TESARO and Tizona Therapeutics. Arnie holds an A.B. degree from New York University, a Ph.D. in Immunology from Columbia University and is a senior lecturer at Johns Hopkins Medical School.

arnie-oronsky

Shawn Tomasello

Director

Shawn Tomasello joined the Centrexion Therapeutics board of directors in 2017. With over 30 years of experience in the pharmaceutical and biotech industries, Shawn currently serves as chief commercial officer of Kite Pharma. Prior to her role at Kite Pharma, Shawn served as chief commercial officer at Pharmacyclics, Inc., preceding its acquisition by AbbVie, Inc. She also held various senior leadership roles at Celgene Corporation, including president of the Americas, hematology and oncology. Earlier in her career, Shawn held positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. She currently serves on the board of Oxford BioTherapeutics and Diplomat Rx. Shawn received her B.S. in marketing from the University of Cincinnati and her MBA from Murray State University.

Shawn-Tomasello